Clinical development of phosphatidylinositol 3-kinase inhibitors for cancer treatment
<p>Abstract</p> <p>The phosphatidylinositol 3-kinase (PI3K) pathway is commonly deregulated in cancer. In recent years, the results of the first phase I clinical trials with PI3K inhibitors have become available. In comparison to other targeted agents such v-raf murine sarcoma vira...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2012-12-01
|
| Series: | BMC Medicine |
| Subjects: | |
| Online Access: | http://www.biomedcentral.com/1741-7015/10/161 |